hyperlipidemia comprising administering to said mammal

(a) an amount of a first compound, said first compound being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(b) an amount of a second compound, said second compound being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first compound and said second compound are administered together in a single pharmaceutical composition with a pharmaceutically acceptable carrier or diluent.

186.(new) The method of claim 185 comprising amlodipine besylate.

187.(new) The method of claim 186 comprising the hemicalcium salt of atorvastatin.

188.(new). The method of claim 185 comprising the hemicalcium salt of atorvastatin.

189.(new) A method of treating a mammal which has been diagnosed as suffering from hypertension and hyperlipidemia or the risk of hypertension and hyperlipidemia which would benefit from therapy by the combined administration of the active ingredients designated as (a) and (b) below, and therefore administration of both (a) and (b) has been prescribed, which comprises administering to said mammal so diagnosed and prescribed

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are administered together in a single pharmaceutical composition with a pharmaceutically acceptable carrier or diluent.

190.(new) The method of claim 189 wherein active ingredient (a) is amlodipine besylate.

191.(new) The method of claim 190 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

192.(new) The method of claim 189 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

193.(new) A method of treating combined hypertension and hyperlipidemia in a mammal which has been examined for both hypertension and hyperlipidemia by a medical practitioner and diagnosed as in need of therapy for said hypertension and hyperlipidemia by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are administered together in single pharmaceutical composition with a pharmaceutically acceptable carrier or diluent.

194.(new) The method of claim 193 wherein active ingredient (a) is amlodipine besylate.

195.(new) The method of claim 194 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

196.(new) The method of claim 193 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

Remarks

Upon entry of the Second Supplemental Amendment, the claims will be 185 to 196. The Examiner telephoned the undersigned on February 28, 2002 and indicated that claims directed to the treatment of hypertension and hyperlipidemia by a single dosage form would be immediately allowable. A draft Second Supplemental Amendment was faxed to the Examiner on March 4, 2002. The Examiner telephoned Gerard M. O'Rourke, an attorney for Applicants on March 5,